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ABSTRACT 
Ameloblastin, the most abundant non-amelogenin enamel matrix protein, plays a role in 
ameloblast differentiation. Here we found that ameloblastin was expressed in osteosarcoma 
cells; to explore the potential functions of ameloblastin in osteoblasts, we investigated 
whether this protein is involved in osteogenic differentiation and bone formation on the 
premise that CD63, a member of the transmembrane-4 glycoprotein superfamily, interacts 
with integrins in the presence of ameloblastin. Ameloblastin bound to CD63 and promoted 
CD63 binding to integrin β1. The interaction between CD63 and integrin β1 induced Src 
kinase inactivation via the binding of CD63 to Src. The reduction of Src activity and 
osteogenic differentiation mediated by ameloblastin was abrogated by treatment with 
anti-CD63 antibody and overexpression of constitutive active Src, respectively. Moreover, 
amelobastin upregulated the formation of stress-fibre and focal adhesions and downregulated 
cell migration in association with RhoA regulation via Src activity. Therefore, our results 
suggest that ameloblastin is expressed in osteoblasts and functions as a promoting factor for 
osteogenic differentiation via a novel pathway through the interaction between CD63 and 
integrin β1.
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INTRODUCTION 
Ameloblastin (AMBN), also known as sheathlin or amelin, is the most abundant 
non-amelogenin enamel matrix protein (6, 9, 19) and a member of the secretory 
calcium-binding phosphoprotein (SCPP) gene cluster of evolutionary-related molecules that 
regulate skeletal mineralization (18). Further, AMBN induces cell attachment, proliferation 
and differentiation of periodontal ligament cells in vitro (46). In AMBN-null mice, 
ameloblasts are detached from the matrix, lose cell polarity and resume proliferation. 
However, protein expression was not completely inactivated and trancated RNA missing a 
portion of exon 5 and 6 is still translated in AMBN KO mice (42). Therefore, it is conceivable 
that exon 5 and 6 of AMBN plays a role in ameloblast differentiation (11, 42). In this mouse 
model, structural change was shown in the alveolar bone (42): the alveolar bone exhibited 
more porosity in truncated AMBN-expressing mice than in wild-type mice. The changes in 
alveolar bone in AMBNΔ5-6 mice cannot be directly related to the protein, as they could arise 
from other factors such as changes in occlusal forces in teeth without enamel (42). On the 
other hand, it has recently been reported that AMBN is expressed in osteoblasts during 
craniofacial development (35). Although AMBN may play a significant role not only in tooth 
development but also in bone formation, it is still unclear the role of AMBN in bone 
formation. 
AMBN has been shown to interact with CD63 via a yeast two-hybrid assay (41). 
CD63 is a member of the transmembrane-4 glycoprotein superfamily, also known as the 
tetraspanin family (36, 44). Most of these proteins are cell-surface proteins that are 
characterized by the presence of four hydrophobic domains and two extracellular domains (36, 
44). CD63 mediates signal transduction events in the regulation of cell survival, development, 
activation, growth and motility (17, 21, 44). In particular, cell-surface CD63 is known to 
complex with integrins (3) and is involved in the control of integrin outside-in signalling 
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activity (13, 17).   
Integrins are heterodimeric adhesion receptors for extracellular matrix proteins 
consisting of α- and β-subunits. Osteoblast differentiation is induced by the aggregation of 
cell-surface α2β1-integrin with matrix type I collagen (16, 38, 43), an event triggered by the 
stimulation of integrins through the association of their cytoplasmic domain with focal 
adhesion kinase, Src and other cytosolic non-receptor tyrosine kinases. Src is a non-receptor 
tyrosine kinase found in a wide variety of tissues (31) and has two important phosphorylation 
sites in Tyr at 416 and 527 (32). Src phosphorylated at Tyr527 interacts with the Src SH2 
domain at the intramolecular level and exhibits a kinase constitutively negative. On the other 
hand, Tyr416 of Src is present within a kinase domain and phosphorylation of Tyr416 
augments kinase activity. Src-deficient mice have an osteopetrotic phenotype (34) and the 
reduction of Src activity stimulates osteoblast differentiation and bone formation (22). In this 
study, to explore further the potential functions of AMBN in osteoblasts, we investigated 
whether this protein is involved in osteogenic differentiation and bone formation according to 
the hypothesis that CD63 interacts with integrins in the presence of AMBN.   
 
MATERIAL AND METHODS 
Reagents and antibodies. Monensin for inhibiting secretion was obtained from Sigma (St. 
Louis, MO, USA). Src-Y527F mutant vector was donated by Addgene, Inc. (Cambridge, MA, 
USA). For detecting endogenous AMBN by immunohistochemistry, an anti-AMBN 
polyclonal antibody (W59), which was generated in rabbits by immunization with synthetic 
peptides (EHETQQYEYS) corresponding to residues 93 to 102 of human AMBN with amino 
acid sequence homology to mice and rat, was used. Commercial antibodies were purchased 
from the following suppliers: anti-FLAG monoclonal antibody (M2) and anti-β-actin 
monoclonal antibody from Sigma; anti-Src polyclonal antibody and polyclonal antibody 
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specific to phospho-Tyr416 Src from Cell Signaling Technology (Danvers, MA, USA); 
anti-integrin β1 (M-106) polyclonal antibody and anti-CD63 (MX-49.129.5) monoclonal 
antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA). CD63 blocking antibody 
(H-193) was purchased from Santa Cruz Biotechnology, and Integrin ß1 blocking antibody 
(MAB2253Z) was purchased from Chemicon (Temecula, CA, USA). 
 
Cell culture of fetal rat calvaria cells. Tweny-one-day-old fetal Wistar rat calvaria cells 
were isolated by sequential collagenase digestion, which resulted in five cell fractions. Briefly, 
calvariae were dissected free from loosely adherent connective tissues, minced, and 
sequentially digested in collagenase (type I; Sigma-Aldrich Corp., St. Louis, MO) solution. 
Cells from the last four of five digestion fractions were separately grown in αMEM 
supplemented with 10% fetal bovine serum (Cansera, Etobicoke, Canada) and antibiotics. 
After 24 h, cells were trypsinized, pooled, and grown in 24-well plates or 35-mm dishes 
(0.3x104 cells/cm2) in the same medium supplemented additionally with 50 µg/ml ascorbic 
acid. All cultures were maintained at 37 ºC in a humidified atmosphere with 5% CO2, and 
medium was changed every second or third day. 
 
Cell lines and tissue samples. Human osteosarcoma cell lines (NOS-1, SaOS-2, MG63 and 
HOS) were provided by Cell Bank, RIKEN BioResource Center (Ibaraki, Japan). They were 
maintained in RPMI-1640 or Dulbecco’s modified Eagle’s Medium (Nissui Pharmaceutical 
Co., Tokyo, Japan) supplemented with 10% heat-inactivated FBS (Invitrogen, Carlsbad, CA, 
USA) and 100 U/ml penicillin-streptomycin (Invitrogen) under 5% CO2 in air at 37°C. Tissue 
samples of osteosarcoma were retrieved from the Surgical Pathology Registry of Hiroshima 
University Hospital, after approval by the Ethical Committee of Hiroshima University 
Hospital. Six osteosarcoma tissue samples were used for the immunohistochemical analysis. 
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Immunohistochemical staining. Immunohistochemical detection of AMBN in the tissue 
samples was performed on 4.5 µm sections mounted on silicon-coated glass slides, by using a 
streptavidin-biotin peroxidase technique as described previously (40). For the 
immunohistochemical study, the anti-AMBN polyclonal antibody (W59) was used. 
 
Immunofluorescence. NOS-1 and SaOS-2 cells as well as AMBN-overexpressing SaOS-2 
cells were seeded on cover slips and grown to approximately 80% confluence. Before fixing, 
monensin was added to the NOS-1 cells at a final concentration of 5 µM for 4 h. The cells 
were fixed in 4% paraformaldehyde for 10 min at room temperature, rinsed thrice with 
ice-cold PBS and then permeabilized in 0.1% Triton X-100 in PBS for 15 min at room 
temperature. After rinsing three times with PBS, the cover slips were incubated with the 
primary antibodies in PBS. We used anti-AMBN polyclonal antibody (W59), 
anti-phospho-Tyr antibody (4G10; Millipore, Billerica, MA, USA) and Alexa Fluor 594 
phalloidin (Molecular Probes, Eugene, OR, USA) as the primary antibodies and anti-rabbit 
Alexa 488 (Molecular Probes) as the secondary antibody. DNA was visualized by 
4′,6-diamidino-2-phenylindole (DAPI) staining. Immunostaining of the cell preparations was 
recorded by using an epifluorescence Zeiss Axioplan 2 microscope (Zeiss, Inc., Thornwood, 
NY, USA) attached to a CCD camera. 
 
Generation of AMBN-overexpressing SaOS-2 cells. Human AMBN cDNA was isolated 
from the cDNA of NOS-1 cells by RT-PCR using sense and antisense primers. The cDNA was 
then subcloned by insertion into the EcoRI/BamHI restriction site of pcDNA3.1, and the 
vector was modified by insertion of a FLAG-tag sequence behind the signal peptide sequence 
using a mutagenesis kit (Stratagene, La Jolla, CA, USA). The AMBN-pcDNA3.1 plasmid or 
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the vector alone was introduced into SaOS-2 cells, and stable clones were obtained by G418 
selection (500 µg/ml, Invitrogen) in the culture medium. Cell transfection was performed by 
using FuGENE 6HD (Roche, Basel, Switzerland) according to the manufacturer’s instruction. 
Conditioned media from control and AMBN overexpressing cells was collected after 48 h of 
plating. 
 
Silencing by siRNA. Logarithmically growing NOS-1 cells were seeded at a density of 105 
cells/dish (6 cm) and transfected with oligos twice (at 24 and 48 h after replating) by using 
Oligofectamine (Invitrogen). Forty-eight hours and ninety-six hours after the last transfection, 
the cells were prepared and analysed by real-time RT-PCR and mineralization assay, 
respectively. The siRNA is a 19-bp duplex oligoribonucleotide with a sense strand 
corresponding to nucleotides 1205–1223 of the human AMBN mRNA sequence: 
5’-ugaccacauccguggauuu-3’. A scrambled sequence without significant homology to rat, 
mouse or human gene sequences was used as a control.   
 
RT-PCR and real-time RT-PCR analysis. Total RNA was isolated from cultures of 
confluent cells by using an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. The preparations were quantified, and their purity was 
determined by standard spectrophotometric methods. cDNA was synthesized from 1 µg total 
RNA according to the ReverTra Dash (Toyobo Biochemicals, Tokyo, Japan). The RT-PCR 
oligonucleotide primers for human, mouse or rat AMBN, CD63, runt-related transcription 
factor 2 (RUNX2), bone morphogenetic protein 2 (BMP2), alkaline phosphatase (ALP), type 
1 collagen (COL I), bone sialoprotein (BSP), osteocalcin (OCN) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are listed in Table 1. Aliquots of total 
cDNA were amplified with 1.25 U rTaq-DNA polymerase (Qiagen) in a PC701 thermal cycler 
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(Astec, Fukuoka, Japan) for 25-30 cycles after denaturation for 30 s at 94°C, annealing for 30 
s at 60°C and extension for 1 min at 72°C in the case of all the primers. The amplified 
products were resolved on 1.5% agarose/TAE gels (Nacalai Tesque, Inc., Kyoto, Japan), 
electrophoresed at 100 mV and visualized by ethidium-bromide staining. For real-time PCR, 
aliquots of total cDNA were amplified with Fast SYBR Green Master Mix (Applied 
Biosystems, Foster City, CA, USA). Data acquisition and analysis were performed with a Step 
One Real Time PCR System using Step One Software V 2.1 (Applied Biosystems). 
 
Generation of recombinant human AMBN. The full-length human AMBN cDNA-inserted 
FLAG-tag sequence was subcloned into pEU vector (CellFree Sciences, Yokohama, Japan), 
which was then transcribed into mRNA. The total mRNA product was translated by using 
WEPRO 3240 according to the manufacturer’s instructions (CellFree Sciences). 
 
Mineralization assay. Mineral nodule formation was detected by the Dahl method for 
calcium (5). Cells were placed in a 24-well or 6-well plate at a density of subconfluence per 
well and cultured in medium supplemented with 10% FBS, 50 µg/ml ascorbic acid and 5 mM 
sodium β-glycerophosphate at 37°C for a week. The cells were fixed in 70% ethanol for at 
least 1 h and then stained with alizarin red S (ALZ). After mineral deposits were stained and 
photographed, the staining was destained with 10% (w/v) cetylpyridinium chloride (Tokyo 
Chemical Industry Co., Ltd., Tokyo, Japan) and the concentrations were determined by the 
absorbance measured at 562 nm on a multiplate reader. 
 
Western blot and immunoprecipitation analyses. Western blotting was carried out as 
described previously (40). Thirty micrograms of protein was subjected to 10% 
polyacrylamide gel electrophoresis followed by electroblotting onto a nitrocellulose filter. For 
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detection of the immunocomplex, the ECL western blotting detection system (Amersham) 
was used. The immunoprecipitates were subjected to immunoblot analysis. For detecting 
CD63–integrin interaction, cell lysates were obtained by lysing the cell monolayer with 1% 
Brij 96 lysis buffer containing 1% Brij 96, 25 mM Hepes (pH 7.5), 150 mM NaCl and 5 mM 
MgCl2.  
 
RESULTS 
AMBN expression in osteosarcoma samples and cell lines. To determine the expression of 
AMBN during proliferation-differentiation-maturation sequence of osteogenic cells in vitro, 
rat embryonic calvalia cell populations were obtained and examined for AMBN expression by 
RT-PCR analysis (Fig. 1A). Under growth conditions, AMBN mRNA was detected in 
exponentially growing cells, but its expression was clearly downregulated when cells reached 
confluence (7 day) (Fig. 1A). At early osteogenic differentiation to late maturation stages, the 
osteoblast markers ALP, a relatively early marker of osteoblast differentiation and OCN, later 
markers of osteoblast differentiation were upregulated (Fig. 1A). These findings suggest that 
AMBN may be involved in early stage of osteogenesis. 
Osteosarcoma cell lines are often used for studying the mechanisms that control 
osteoblast-specific gene expression. To investigate the detailed role of AMBN in osteogenesis, 
we used osteosarcoma cells. We found that osteosarcoma cell line, NOS-1 cells expressed 
AMBN mRNA (Fig. 1B). NOS-1 cells also showed the expression of RUNX2, ALP, COL I, 
BSP and OCN mRNA (Fig. 1B). In NOS-1 cells, the expression of AMBN in the cytoplasm 
by immunofluorescence analysis in the presence of monensin for inhibiting the secretion (Fig. 
1C). We also examined the immunohistochemical expression of AMBN in six 
paraffin-embedded osteosarcoma samples. We checked the specificity of AMBN antibody in 
ameloblasts of a 7-day-old mouse. The sequence specificity of AMBN antibody used in this 
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study was conserved between mice and humans. The AMBN antibody specifically recognized 
AMBN in ameloblasts (Fig. 1D). By using this antibody, we found the expression of AMBN 
in two of the samples (Fig. 1D). Therefore, we demonstrated that the osteosarcoma cells 
expressed AMBN. 
 
Involvement of AMBN in osteogenic differentiation and mineralization. To explore the 
involvement of AMBN in osteoblastic activity, we examined osteogenic differentiation and 
mineralization in NOS-1 cells treated with AMBN siRNA. In the AMBN siRNA-treated cells, 
AMBN mRNA expression was reduced (Fig. 2A). Interestingly, remarkable downregulation 
of ALP, COL I and BSP mRNA was observed in AMBN-knockdown cells in comparison with 
the control cells (Fig. 2A). Moreover, when the control and AMBN-knockdown cells were 
cultured for 4 days in the presence of osteogenic media containing β-glycerophosphate and 
ascorbic acid after transfection with AMBN siRNA for 48 h, matrix mineralization was found 
to be decreased in the AMBN-knockdown cells (Fig. 2B). 
To elucidate the detailed role of AMBN in mineralization, we examined ectopic 
overexpression of AMBN by transfection of the pcDNA3.1-AMBN vector with insertion of 
FLAG-tag sequences behind signal peptide sequences into SaOS-2 cells without AMBN 
expression (Fig. 3A). We obtained SaOS-2 cells with stable AMBN overexpression (Fig. 3B). 
In the conditioned media from AMBN-overexpressing SaOS-2 cells, several bands were 
detected by Western blotting using anti-FLAG antibody, indicating that AMBN might have 
been modified after secretion (Fig. 3C). As expected, the upregulation of RUNX2 and BSP 
mRNA expression (Fig. 3D) and promotion of matrix mineralization were observed in the 
AMBN-overexpressing SaOS-2 cells (Fig. 3E). We also confirmed that treatment with 
recombinant human FLAG-AMBN enhanced matrix mineralization in the SaOS-2 cells, as 
seen in AMBN overexpression (Fig. 3F and 3G). 
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Regulation of Src kinase activity via interaction between integrin and CD63. We next 
investigated the mechanism of AMBN for promoting osteogenic differentiation and 
mineralization. On the basis of our hypothesis that CD63 interacts with integrins in the 
presence of AMBN, we first examined the expression of CD63 and integrin β1 in the 
osteosarcoma cell lines. These cell lines expressed CD63, and especially, the SaOS-2 cells 
expressed CD63 strongly (Fig. 4A). The CD63 protein, being heavily glycosylated, exhibited 
diffuse distribution on SDS-PAGE, as previously reported (17, 36). To determine the 
interaction between CD63 and AMBN, we performed immunoprecipitation using anti-FLAG 
and anti-CD63 antibodies in FLAG-AMBN-overexpressing SaOS-2 cells. As shown in Fig. 
4B, ectopic AMBN bound to CD63 in the AMBN-overexpressing cells. Then, to examine the 
intracellular signalling event in the AMBN-overexpressing cells, we examined the Src activity 
in control and AMBN-overexpressing cells by using phospho-Tyr416 Src antibody. Tyr416 of 
Src is present within a kinase domain and phosphorylation of Tyr416 augments the kinase 
activity. Interestingly, the level of phospho-Tyr416 Src was remarkably low in the 
AMBN-overexpressing cells compared with the control cells (Fig. 4C). To know the cell 
adhesion-dependent autophosphorylation of Src Tyr416 in AMBN-overexpressing cells, we 
examined the phosphorylation levels of Src at Tyr416 in control and AMBN-overexpressing 
cells at 0, 30 and 60 min after attachment on COL I-coated dishes. The phosphorylation levels 
of Src were found to be as low in these AMBN-overexpressing cells as in those under the 
normal condition (Fig. 4C). We also examined the expression of the phosphorylation levels of 
Src at Tyr416 in AMBN siRNA transfected NOS-1 cells. AMBN knockdown upregulated the 
phosphorylation level of Tyr416 of Src (Fig. 4D). To investigate the crosstalk among integrin 
β1, CD63 and Src, we performed immunoprecipitation with anti-CD63 antibody in control 
and AMBN-overexpressing cells after 48 h of attachment on COL I-coated dishes. Only in the 
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AMBN-overexpressing cells, CD63 bound to integrin β1 and Src (Fig. 4E). These findings 
suggested that the interaction between CD63 and integrin β1 inhibited Src activity in the 
presence of AMBN. 
To support these established roles of AMBN in regulating osteogenesis via CD63, 
we examined the inhibition of the osteogenic function of CD63 using CD63 blocking 
antibody in control and AMBN-overexpressing cells. Previous report shows that AMBN 
interacts with amino acids 103–205 of the human CD63 protein where is hydrophobic and 
accessible to the external environment, demonstrated by yeast-two hybrid assay (47). CD63 
blocking antibody used in this study is raised against amino acids 45-238 mapping at human 
CD63 protein. Indeed, we confirmed that CD63 blocking antibody interrupted the interaction 
of CD63 with AMBN (data not shown). On Western blot analysis using anti-phospho-Tyr416 
Src antibody, reduced phosphorylation levels of Src in AMBN-overexpressing cells were 
observed without anti-CD63 treatment, but pretreatment with anti-CD63 antibody induced the 
upregulation of the phosphorylation levels (Fig. 5A). Interestingly, pretreatment with 
anti-CD63 antibody blocked the promotion of mineralization in SaOS-2 cells treated with the 
conditioned media from AMBN-overexpressing cells (Fig. 5B). To know the involvement of 
integrin ß1 in the inhibition of Src activity by AMBN overexpression, we treated the integrin 
ß1 blocking antibody in AMBN-overexpressing cells. Treatment with integrin ß1 blocking 
antibody upregulated phosphorylation levels of Src at Tyr416 in AMBN-overexpressing cells 
(Fig. 5C). Interestingly, treatment with integrin ß1 blocking antibody decreased the expression 
of RUNX2, ALP, COLI, BSP and OCN mRNA (Fig. 5D). 
Moreover, we examined whether Src activation inhibits the AMBN-mediated 
mineralization by transfection of constitutive active mutant of Src (Y527F) in 
AMBN-overexpressing cells. Transfection of the constitutive active mutant of Src upregulated 
the phosphorylation level of Src at Tyr416 (Fig. 6A). Interestingly, matrix mineralization was 
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inhibited by Src activation in the AMBN-overexpressing cells (Fig. 6B). Further, RUNX2, 
ALP and BSP were downregulated by Src activation in these cells (Fig. 6C). These findings 
indicated that the AMBN-CD63 axis inhibited Src activation, which in turn promoted 
mineralization and osteogenic differentiation. 
We examined the effects of AMBN and/or CD63 in normal mouse osteoblastic cell 
line, MC3T3-E1. CD63 was expressed in osteosarcoma cell lines but not in normal mouse 
osteoblastic cell lines ST2 and MC3T3-E1 (Fig. 7A). We transiently transfected AMBN 
and/or CD63 into MC3T3-E1 cells (Fig. 7B). Although mineral deposit was not remarkably 
promoted by ectopic AMBN and AMBN/CD63 (data not shown), ectopic expression of 
AMBN upregulated RUNX2, BSP and OCN, and ectopic expression of AMBN/CD63 
upregulated BSP (Fig. 7C). 
 
DISCUSSION  
AMBN is an ameloblast-specific glycoprotein, and AMBN is localized to human chromosome 
4q21 within the autosomal dominant amelogenesis imperfecta locus (24), suggesting that this 
protein is important for enamel formation. AMBN is present in the secretory stage of enamel 
formation, as demonstrated by immunostaining of ameloblastin (29). It has recently been 
revealed that AMBN is also expressed in osteoblasts during craniofacial skeletal development 
and in an osteosarcoma cell line, SaOS-2, cultivated on biosilica matrices (25, 35). However, 
the function of AMBN in osteoblasts is unknown. Here, we found that AMBN promoted 
mineralization through the inhibition of Src activation in osteosarcoma. This is the first report 
on the function of AMBN in osteogenesis. We found an osteosarcoma cell line with high 
expression of AMBN. Interestingly, knockdown of AMBN inhibited the formation of 
mineralization deposits in this cell line. In fact, AMBN was found to induce osteogenic 
differentiation and promote mineralization by ectopic AMBN overexpression and 
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recombinant human AMBN treatment. In particular, RUNX2, ALP and BSP mRNA 
expressions were upregulated by AMBN overexpression and downregulated by AMBN 
knockdown. RUNX2, ALP and BSP are osteogenic markers, and enhance osteogenic 
differentiation and matrix mineralization (1, 12). Therefore, we suggest that increased 
expression of RUNX2, ALP and BSP by AMBN overexpression may promote osteogenic 
differentiation. AMBN, a 65-70 kDa protein, is rapidly processed into several 
lower-molecular-weight proteins ranging from 52 kDa to 13 kDa (29). AMBN is cleaved by 
MMP-20 (enamelysin), which is an ameloblast-specific gene (15). The cells of bone lineage 
don’t express any traces of MMP-20 (data not shown). Defects of MMP-20 function cause 
autosomal-recessive amelogenesis imperfecta (27). In this study, we found that secreted 
AMBN protein was cleaved in the conditioned media from AMBN-overexpressing 
osteoblastic cells (Fig. 3C). It is likely that AMBN is cleaved by proteases other than 
MMP-20 in osteosarcoma cells. Moreover, osteogenic differentiation mediated by AMBN 
may be promoted by cleaved functional AMBN fragments in osteosarcoma. 
Although AMBN has been shown to interact with CD63 (41), the physiological role 
of this interaction is still unclear. As we found an interaction between AMBN and CD63 in 
osteosarcoma cells, the function of this interaction in osteogenesis was examined. In 
osteosarcoma cells with AMBN expression, CD63 blocking antibody suppressed 
mineralization. Previous studies have shown that cell-surface CD63 forms a complex with 
integrins (3) and that CD63 binds with Src and increases the phosphorylation of Src at Tyr416 
(20). In this study, we found that CD63 bound to Src and integrin β1 in the presence of 
AMBN. Interestingly, AMBN stimulation inhibited Src activation, and AMBN-promoted 
osteogenic differentiation and mineralization was disrupted by constitutive active Src 
overexpression. Indeed, AMBN knockdown suppressed osteogenic differentiation through Src 
activation (Fig. 2A, 2B and 4D). Moreover, the treatment with CD63 blocking antibody or 
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integrin ß1 blocking antibody induced Src activation (Fig. 5A-D). These findings suggest that 
the AMBN-CD63-integrin axis may promote osteogenesis through Src inactivation (Fig. 8). 
Previous reports have demonstrated that Src-deficient mice develop osteopetrosis by 
accelerated osteogenic differentiation (22, 34) and that osteoblast differentiation mediated by 
the reduction of Src kinase activity is regulated by osteocalcin expression via the interaction 
between RUNX2 and Yes-associated protein (45). Thus, our findings provide evidence for the 
novel mechanism of AMBN-mediated osteogenic differentiation. Therefore, AMBN can be a 
therapeutic modality for bone regeneration. Osteosarcoma cells present osteoblastic 
differentiation and form tumoural bone in similar to osteoblasts. In the present study, CD63 
was expressed in osteosarcoma cell lines but not in normal mouse osteoblastic cell lines ST2 
and MC3T3-E1 (Fig. 7A). CD63 is reportedly expressed in human mesenchymal stem cells 
undergoing osteogenic differentiation (10). As neoplastic cells have a potential to undergo 
divergent differentiation, CD63 expression may be observed in osteosarcoma cells. The 
effects of AMBN on osteoblasts may be regulated by spatiotemporal interactions between 
AMBN and CD63 during bone development and bone healing process. In fact, ectopic 
expression of AMBN upregulated RUNX2, BSP and OCN, and ectopic expression of 
AMBN/CD63 upregulated BSP in normal mouse osteoblastic cell line, MC3T3-E1 (Fig. 7C). 
However, mineral deposit was not remarkably promoted by ectopic AMBN and AMBN/CD63 
in MC3T3-E1 cells (data not shown). These findings suggest that additional factor may be 
required for AMBN-promoted osteogenic differentiation in normal osteoblasts.  
In conclusion, our study has revealed an important role of AMBN in osteogenic 
differentiation via the AMBN-CD63-integrin-Src axis. Our findings may help to clarify the 
pathway involved in osteogenesis. 
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Figure legends 
FIG.1. AMBN expression in ostesarcoma cells. (A) Outline of differentiation and treatment 
protocols during typical time windows of rat calvaria cell cultures (left panel). Cells (0.3x104 
cells/cm2) reach confluence at approximately 7 day and subsequently initiate nodule 
formation. Cells are at exponential proliferation/primitive progenitor stages before confluence 
and at early osteogenic differentiation to late maturation stages after confluence to culture 
termination. Rat calvaria cells were collected at 3, 7, 10 and 14 day. Expression of AMBN, 
CD63, ALP and OCN mRNA was examined by RT-PCR (right panel). GAPDH expression 
was used as a control. (B) mRNA expression of AMBN and mineralization-related molecules 
RUNX2, BMP-2, ALP, COL I, BSP and OCN in osteosarcoma cell lines NOS-1, SaOS-2, 
MG63 and HOS by RT-PCR. GAPDH mRNA expression was used as the control. (C) 
Intracellular AMBN expression (green) after monensin treatment and DAPI staining for nuclei 
(blue) in NOS-1 cells. The merged image is also shown. (D) Immunohistochemical expression 
of AMBN in osteosarcoma tissues. To check the specificity of an anti-AMBN antibody, 
immunohistochemical expression of AMBN was examined in ameloblasts of developing teeth 
of a 7-day-old mouse (left panel). Arrow and arrowhead indicates ameloblastic layer of lower 
incisor and lower first molar, respectively. Asterisk is enamel matrix. Immunohistochemical 
expression of AMBN in the osteosarcoma tissues (case No.1 and No.2) (right panel). 
 
FIG. 2. Suppression of osteogenic differentiation and mineralization by AMBN knockdown. 
(A) mRNA expression levels of AMBN and mineralization-related molecules in control 
(scramble-siRNA) and AMBN siRNA-transfected NOS-1 cells were examined by real-time 
RT-PCR. The data are shown as the ratio of each mRNA to GAPDH mRNA and the values are 
expressed as the mean ± S.D. (N = 3); *P < 0.05 (t-test). (B) Control and AMBN 
siRNA-transfected NOS-1 cells were cultured for 4 days in the absence or presence of 50 
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µg/ml ascorbic acid (AA) and 5 mM sodium β-glycerophosphate (βGP). ALZ staining was 
performed to visualize mineral deposition. 
 
FIG. 3. AMBN enhanced osteogenic differentiation and mineralization. (A) The structure of 
the pcDNA3.1-AMBN vector, which was modified by insertion of a sequence encoding 
FLAG-tag behind the signal peptide sequence. (B) SaOS-2 cells were stably transfected with 
the vector for FLAG-AMBN. The transient and stable expression of AMBN in SaOS-2 cells 
was examined by Western blot analysis using anti-FLAG antibody. The asterisk indicates 
non-specific bands. (C) Ectopic expression of FLAG-AMBN in the conditioned media (CM) 
from stably transfected cells was examined by Western blot analysis using anti-FLAG tag 
antibody. Arrowhead indicates the fragment of AMBN in conditioned media. (D) The mRNA 
expression levels of mineralization-related molecules in control (pcDNA3.1) and 
AMBN-overexpressing cells were assessed by real-time RT-PCR. The data are shown as the 
ratio of each mRNA to GAPDH mRNA and the values are expressed as the mean ± S.D. (N = 
3); *P < 0.05 (t-test). (E) Control and AMBN-overexpressing cells were cultured for 10 and 
15 day in the presence of 50 µg/ml ascorbic acid and 5 mM sodium β-glycerophosphate. After 
mineral deposits were stained and photographed, the staining was destained by using 10% 
(w/v) cetylpyridinium chloride and the concentrations were determined by the absorbance 
measured at 562 nm on a multiplate reader. The picture shows mineral deposits at 15 day. The 
absorbance of the control cells at 10 days was defined as 1. The graph shows the relative ALZ 
levels. (F) Recombinant AMBN promotes mineralization in osteosarcoma cells.AMBN 
full-length protein including FLAG-tag (rhAMBN) were produced by Wheat Germ Cell-Free 
System and were examined by Western blot using anti-FLAG tag antibody. We also used 
control recombinant protein (rCtrl). (G) SaOS-2 cells cultured for 10 days in the presence of 
50 mg/ml ascorbic acid and 5 mM sodium b-glycerophosphate and also each cells cultured on 
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normal dish, control recombinant protein coated dish (rCtrl) and 10 μg/ml of recombinant 
AMBN coated dish (rAMBN). After mineral deposits were stained and photographed, the 
staining was destained by 10% (w/v) cetylpyridinium chloride and the concentration were 
determined by absorbance measurement at 562 nm on a multiplate reader. The absorbance of 
control cells at 10 days is defined as 1. Graph shows relative ALZ levels. 
FIG. 4. Src phosphorylation via the AMBN-CD63-integrin β1 axis. (A) Expression of CD63 
(long and short exposure) and integrin β1 in osteosarcoma cell lines was detected by Western 
blot analysis. β-actin was used as a loading control. (B) Interaction between AMBN and 
CD63 in FLAG-AMBN-overexpressing SaOS-2 cells was examined by immunoprecipitation 
with anti-FLAG or anti-CD63 antibody. The arrowheads show immunoprecipitated 
FLAG-AMBN or CD63. (C) Phosphorylation status of Src at Tyr416 in control and 
FLAG-AMBN-overexpressing cells under the condition of adhesion and suspension. For 
suspension, the control and AMBN-overexpressing cells were detached after trypsinization 
and kept in suspension at 37°C for 2 h. Then, they were collected after plating on COL 
I-coated dishes for 0, 30 and 60 min. The cell lysates were immunoblotted with 
phospho-Tyr416 Src and Src antibody. β-actin expression was used as a loading control. (D) 
We transfected AMBN siRNA into NOS-1 cells. The cell lysates were immunoblotted with 
phospho-Tyr416 Src, Src and integrinß1 antibody. β-actin expression was used as a loading 
control. (E) Lysates of the control and AMBN-overexpressing cells were immunoprecipitated 
with anti-CD63 antibody and immunoblotted with anti-integrin β1 or anti-Src antibody. The 
arrowheads indicate immunoprecipitated integrin β1 or Src. The expressions of integrin β1 
and Src were examined in whole cell lysates by Western blot analysis to show equal amounts 
of protein. 
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FIG. 5. AMBN induced osteoblast mineralization via CD63 and Src interaction. (A) After 
suspension culture with or without CD63 blocking antibody, lysates of control and 
AMBN-overexpressing cells plated on COL-1-coated dish for 60min were immunoblotted 
with anti-phospho-Tyr416. The asterisk indicates IgG of CD63 antibody and the arrowhead 
indicates Src phosphorylation at Tyr416. β-actin was used as a loading control. (B) SaOS-2 
cells were cultured for 10 days after pre-suspension at 37 ℃ for 2h in the presence of 50 
µg/ml ascorbic acid and 5 mM sodium ß-glycerophosphate with or without CD63 blocking 
antibody and conditioned medium (CM) from control or AMBN-overexpressing cells. ALZ 
staining was performed to visualize mineral deposition. ALZ was destained by using 10% 
(w/v) cetylpyridinium chloride and the concentrations were determined by measuring the 
absorbance at 562 nm. The values are expressed as the mean ± S.D. (N = 3); *P < 0.05 (t-test). 
(C) Integrin ß1 blocking antibody was used at a concentration of 1 μg/ml and incubated for 
3h. In control and AMBN-overexpressing SaOS cells, treatments were repeated every 3h to a 
total of four treatments in 12h. The cell lysates were immunoblotted with phospho-Tyr416 Src, 
Src and FLAG antibody. β-actin expression was used as a loading control. (D) In control and 
AMBN-overexpressing SaOS cells after treatment with integrin ß1 blocking antibody, mRNA 
expression levels of AMBN, CD63, RUNX2, BSP and OCN were examined by real-time 
RT-PCR. The data are shown as the ratio of each mRNA to GAPDH mRNA and the values are 
expressed as the mean ± S.D. (N = 3). 
 
FIG. 6. (A) SaOS-2, AMBN-overexpressing SaOS-2 and AMBN and constitutive active Src 
mutant (Src-Y527F) cotransfected cells were examined by Western blot analysis by using 
anti-phospho-Tyr416 Src and anti-Src antibodies. β-actin was used as a loading control. (B) 
Control and AMBN-overexpressing cells were cultured for 10 days in the presence of 50 
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µg/ml ascorbic acid and sodium 5 mM β-glycerophosphate after transfection with constitutive 
active Src mutant (Src-Y527F). Then, ALZ staining was performed to visualize mineral 
deposition. ALZ was destained by 10% (w/v) cetylpyridinium chloride and the concentrations 
were determined by measuring the absorbance at 562 nm. The values are expressed as the 
mean ± S.D. (N = 3); *P < 0.05 (t-test). (C) Control and AMBN-overexpressing cells were 
cultured for 4 days after transfection with constitutive active Src mutant (Src-Y527F) and the 
mRNA expression levels of mineralization-related molecules were assessed by real-time 
RT-PCR. The data are shown as the ratio of each mRNA to GAPDH mRNA. The values are 
expressed as the mean ± S.D. (N = 3); *P < 0.05 (t-test). 
 
FIG. 7. (A) Expression of CD63 in ST-2 and MC3T3-E1 cells. CD63 expression was detected 
by Western blot analysis. β-actin was used as a loading control. (B) Ectopic expression of 
AMBN and CD63 in MC3T3-E1 cells. MC3T3-E1 cells were transiently transfected with the 
vector for FLAG-AMBN and/or GFP-CD63. The ectopic expression of AMBN and CD63 in 
MC3T3-E1 cells was examined by RT-PCR. GAPDH mRNA expression was used as the 
control. (C) mRNA expression levels of AMBN, CD63, RUNX2, BSP and OCN in 
MC3T3-E1 cells were examined by real-time RT-PCR. The data are shown as the ratio of 
each mRNA to GAPDH mRNA and the values are expressed as the mean ± S.D. (N = 3). 
 
FIG. 8. Schematic of the molecular mechanism of AMBN in osteogenesis. In this model, 
osteoblasts cultured on COL I-coated dishes show elevation of Src phosphorylation via 
integrin β1 signalling in the absence of AMBN. After stimulation of AMBN, AMBN binds to 
CD63 and CD63 binds to integrin β1. Src binds to CD63 and is dephosphorylated. Finally, 
dephosphorylated Src promotes osteogenic differentiation. 
 
Table 1. Primers used for real time RT-PCR
primer Sequence
CCTTGCAGGAAGGAGAACTG
CTGGGAGTGATGGACCTTGT
TTACTTACACCCCGCCAGTC
TATGGAGTGCTGCTGGTCTG
CCTCCTCGGAAGACACTCTG
GCAGTGAAGGGGCTTCTTGTC
GTGCTAAAGGTGCCAATGGT
ACCAGGTTCACCGCTGTTAC
AACCTACAACCCCACCACAA
AGGTTCCCCGTTCTCACTTT
GACTGTGACGAGTTGGCTGA
CTGGAGAGGAGCAGAACTGG
TCCCTTCCATGTCGAAGAAC
GGCAAAGACAATTCCCAAAA
GCATCCTGGGCTACACTGAG 
TCCACCACCCTGTTGCTGTA  
Human AMBN F
R
Human RUNX2 F
R
Human ALP F
R
Human COLⅠ F
R
Human BSP F
R
Human OCN F
R
Human CD63 F
R
Human GAPDH F
(Mouse/Rat) R
Ambn : ameloblastin, Runx2 : runt-related transcription factor 2, ALP : alkaline phosphatase, 
COLⅠ: type Ⅰ collagen, BSP : bone sialoprotein, OCN : osteocalcin, GAPDH : glyceraldehyde-3-
phosphate dehydrogenase
Table 1
Mouse AMBN F
R
Mouse CD63 F 
R 
Mouse Runx2 F
R
Mouse BSP F
R
Mouse OCN F
R
Mouse ALP F 
R
Rat CD63 F 
R 
Rat ALP F 
R 
Rat OCN F
R
TTCTTGCTTTCCCCAATGAC
GGTGCACTTTGTTTCCAGGT 
GCCATTGCTGGCTATGTGTT
AGAATCGGGGACTCTGTCCT
CGCATTCCTCATCCCAGTAT
TAAAGGTGGCTGGGTAGTGC
ACCGGCCACGCTACTTTCTTT
GACCGCCAGCTCGTTTTCA
AAGCAGGAGGGCAATAAGGT
AGCTGCTGTGACATCCATAC
TCCCTACCGACCCTGTTCTGA
TGGACCTCTCCCTTGAGTGT
TGTTGCCTGTGGTCATCATT
TGGCCGTTTTGTTGTCTGTA
AGGCAGGATTGACCACGG
TGTAGTTCTGCTCATGGA 
CAGCCCCCTACCCAGAT
TGTGCCGTCCATACTTTC 
primer Sequence
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